Basic Information
Prialt
Regulatory Information
EMEA/H/C/000551
Authorised
February 21, 2005
November 18, 2004
31
June 21, 2024
Company Information
Germany
Hohenzollerndamm 150-151 14199 Berlin
Esteve Pharmaceuticals GmbH
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Ziconotide is indicated for the treatment of severe, chronic pain in patients who require intrathecal (IT) analgesia.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Prialt. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Prialt.